Outcome of Ruthenium-106 Brachytherapy for Uveal Melanoma and Retinal Vascular Tumors: A Retrospective Study.

Ru-106 plaque brachytherapy is effective in treating various intraocular tumors, particularly vasoproliferative tumor/retinal capillary hemangioma.

Tumor thickness significantly influences treatment outcomes, emphasizing the need for tailored approaches in brachytherapy planning. However, small sample sizes for specific tumor types limited the generalization of the outcomes.

Future research should focus on refining techniques and mitigating complications to improve patient outcomes in ocular oncology.